Download PDF
Thromb Haemost 1995; 74(01): 486-492
DOI: 10.1055/s-0038-1642726
Symposium
Clinical Uses of Fibrin Sealant
Schattauer GmbH Stuttgart

Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis

Uri Martinowitz
The National Hemophilia Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
,
Sam Schulman
The National Hemophilia Center, The Chaim Sheba Medical Center, Tel Hashomer, Israel
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Brown B, Steed DL, Webster MW, Makaroum MS, Spero JA, Bontempo FA, Ragni MV, Lewis JH. General surgery in adult hemophiliacs. Surgery 1986; 99: 154-159
    PubMedGoogle Scholar
  • 2 Small M, Steven M, Freeman O, Lowe GD O, Belch JJ F, Forbes CD, Prentice CR M. Total knee arthroplasty in haemophilic arthritis. J Bone Joint Surg 1983; 65 B 163-165
    CrossrefPubMedGoogle Scholar
  • 3 Spivack AR, Avioli LV. Orthopedic and medical treatment of patients with hemophilia. Arch Intern Med 1983; 143: 1431-1433
    CrossrefPubMedGoogle Scholar
  • 4 Iwata H, Oishi Y, Itoh A, Ishiguro N, Yamaga H, Miyamoto N, Kamiya T. Surgical excision of hemophilic pseudotumor of ilium. Clin Orth Rel Res 1992; 284: 234-238
    PubMedGoogle Scholar
  • 5 Sindet-Pedersen S. Hemostasis in oral surgery - the possible pathogenic implications of oral fibrinolysis on bleeding. Dan Med Bull 1991; 38: 427-442
    PubMedGoogle Scholar
  • 6 Thomas DP, Lee CA, Colvin BT, Dasani H, Dolan G, Giangrande PL E, Jones P, Lucas G, Cantwell O, Harman CT. Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations. Haemophilia 1995; 1: 17-32
    CrossrefPubMedGoogle Scholar
  • 7 Blatt PM, White CG, McMillan CW, Webster WP. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody. J Am Med Assoc 1984; 251: 67
    CrossrefPubMedGoogle Scholar
  • 8 Parry DH, Bloom AL. Failure of factor VIII inhibitor by passing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies. J Clin Pathol 1978; 31: 1102-1105
    CrossrefPubMedGoogle Scholar
  • 9 Stenbjerg S, Jorgensen J. Resistance to activated FIX concentrate (FEIBA). Scand J Haematol 1977; 18: 421-426
    PubMedGoogle Scholar
  • 10 Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR M. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 30 Suppl (Suppl. 01) 10-21
    PubMedGoogle Scholar
  • 11 Sjamsoedin EJ, Heijmen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentra-te (Feiba) on joint and muscle bleed in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981; 305: 717-721
    CrossrefPubMedGoogle Scholar
  • 12 Kasper CK. Thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-644
    PubMedGoogle Scholar
  • 13 Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factorXIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71 (05) 1336-1341
    CrossrefPubMedGoogle Scholar
  • 14 Glander JA, Nossal R. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30 (03) 273-288
    CrossrefPubMedGoogle Scholar
  • 15 Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp PE, Teller DC. Three dimensional structure of a transglutaminase :human blood coagulation factor XIII. Proc Natl Acad Sci USA 1994; 91: 7296-7300
    CrossrefPubMedGoogle Scholar
  • 16 Tamaki T, Aoki N. Crosslinking of a2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-14772
    PubMedGoogle Scholar
  • 17 Aoki N, Tamaki T, Sakata Y, Ichinose A. Crosslinking of a2-plasmin inhibitor to fibrin, its comparison with fibronectin and its physiological significance. In: Egbring R, Klingemann HG. Eds. Factor XIII and fibronectin. Die Marburg:Medizinische Verlagsgesllschaft 1982: 205-212
    PubMedGoogle Scholar
  • 18 Homyak TJ, Shafer JA. Interaction of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-429
    CrossrefPubMedGoogle Scholar
  • 19 Morten sen SB, Sottrup-Jensen L, Hansen HF, Rider D, Petersen TE, Magnusson S. Sequence location of a putative transglutaminase crosslinking site in human a2 macroglobulin. FEBS 1981; 129: 314-317 (lett)
    CrossrefPubMedGoogle Scholar
  • 20 Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2-plasminogen activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa:transglutaminase-catalyzed crosslinking to cellular and extracellular structures. Eur J Biochem 1993; 214: 141-146
    CrossrefPubMedGoogle Scholar
  • 21 Aeschlimann D, Paulsson M. Transglutaminases-.protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-415 (review)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Hansen MS. Fibronectin and coagulation factor XIII increases blood platelet adhesion to fibrin. Thromb Res 1984; 34 (06) 551-556
    CrossrefPubMedGoogle Scholar
  • 23 Fésus L, Metsis ML, Muszbek L, Koieliansky VE. Transglutaminase- sensitive glutamine residues of human plasma fibronectin, revealed by studying its proteolytic fragments. Eur J Biochem 1986; 154: 371-374
    CrossrefPubMedGoogle Scholar
  • 24 Bale MD, Mosher DF. Effects of thrombospondin on fibrin polymerization and structure. J Biol Chem 1986; 261 (02) 862-868
    PubMedGoogle Scholar
  • 25 Bale MD, Mosher DF. Thrombospondin is a substrate for blood coagulation factor Xllla. Biochemistry 1986; 25 (19) 5667-5673
    CrossrefPubMedGoogle Scholar
  • 26 Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 1988; 157 (01) 115-120
    CrossrefPubMedGoogle Scholar
  • 27 Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. Blood 1986; 68 (01) 95-101
    PubMedGoogle Scholar
  • 28 Mosher DF. Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem 1984; 58: 63-68
    CrossrefPubMedGoogle Scholar
  • 29 Ishikawa-Sakurai M, Hayashi M. Two collagen-binding domains of vitronectin. Cell Struct Funct 1993; 18 (04) 253-259
    CrossrefPubMedGoogle Scholar
  • 30 Bockenstedt P, McDonagh J. andin RL Binding and covalent cross- linking of purified von willebrand factor to native monomeric collagen. J Clin Invest 1986; 78 (02) 551-556
    CrossrefPubMedGoogle Scholar
  • 31 Barry EL, Mosher DF. Factor Xllla-mediated cross-linking of fibronectin in fibroblast cell layers. Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments. J Biol Chem 1989; 264 (07) 4179-4185
    PubMedGoogle Scholar
  • 32 De Palma L, Chriss VR, Luban NL C. The preparation of fibrinogen concentrate for use as fibrin glue by four different methods. Transfusion 1993; 33: 717-720
    PubMedGoogle Scholar
  • 33 Salz R, Dimick A, Harris C, Grotting JC, Psillakis J, Vasconez LO. Application of autologous fibrin glue in bum wounds. J Bum Care Rehabil 1989; 10: 504-507
    PubMedGoogle Scholar
  • 34 Casali B, Rodeghiero F, Tosetto A, Palmieri B, Immovilli R, Ghedini C, Rivasi P. Fibrin glue from single donation autologous plasmapheresis. Transfusion 1992; 32: 641-643
    CrossrefPubMedGoogle Scholar
  • 35 Hartman AR, Galanakis DK, Honig MP, Seifert FC, Anagnostopoulus CA. Autologous whole plasma fibrin glue. Arch Surg 1992; 127: 357-359
    CrossrefPubMedGoogle Scholar
  • 36 Oz MC, Jeevanandam V, Smith CR, Williams MR, Kaynar AM, Frank RA, Mosca R, Reiss RF, Rose EA. Autologous fibrin glue from intraoperatively collected platelet-rich plasma. Ann Thorac Surg 1992; 53: 530-531
    CrossrefPubMedGoogle Scholar
  • 37 Hilfenhaus J, Weidmann E. Fibrin glue safety :inactivation of potential viral contaminants by pasteurization of the human plasma components. Drug Res 1985; 35: 1617-1619
    PubMedGoogle Scholar
  • 38 Cuthbertson B, Reid KG, Foster PR. Viral contamination of human plasma products and procedures for preventing vims transmission by plasma products. In: Blood separation and plasma fractionation. Wiley-Liss 1991; 385-435
    PubMedGoogle Scholar
  • 39 Bumouf-Radosevich M, Bumouf T, Huart JJ. Biochemical and physical properties of solvent detergent treated fibrin glue. Vox Sang 1990; 58: 77-84
    CrossrefPubMedGoogle Scholar
  • 40 Communications at:Fibrin sealantxharacterization and clinical uses.. USUHS; Bethesda,Maryland: 1994
  • 41 Rapaport SI, Zivelin A, Monow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91
    CrossrefPubMedGoogle Scholar
  • 42 Stocker KF. Snake venom proteins affecting hemostasis and fibrinolysis. In: Medical use of snake venom proteins. Stocker KF. ed. Boca Raton, Boston; CRC Press: 1990: 136-140
    Google Scholar
  • 43 Fibrin sealant:Characteristics and clinical uses, Uniform Services University of the Health Sciences. Bethesda; Maryland: 8-9 12/1994
  • 44 Martinowitz U, Ozer Y, Varon D, Engel Y, Yaffe B. Fibrin sealing in nerve repair. Thromb Haemostas 1993; 69: 1287 (abstract)
    PubMedGoogle Scholar
  • 45 Gehringer W, Stadler M, Josic Dj, Biesert L, Nur I, Schwinn H. Octacoha double vims inactivated biological adhesive, derived from human plasma. Thromb Haemostas. 1995 submitted (abstract)
    PubMedGoogle Scholar
  • 46 Hoots K, McLeod J, Eggers E, Berg J, Lee M, Gomperts E. Pilot study to evaluate efficacy of fibrin sealant (human) on hemostasis in hemophiliacs undergoing tooth extractions. Blood 1993; Suppl 82a 598 (abstract)
    PubMedGoogle Scholar
  • 47 Martinowitz U, Mazar AL, Rakocz M, Varon D, Gitel SN, Ramot B. aicher. Dental extraction for patients on oral anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1990; 70: 274-277
    CrossrefPubMedGoogle Scholar
  • 48 Rakocz M, Mazar A, Varon D, Spierer S, Martinowitz U. Dental extractions in patients with bleeding disorders, the use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75: 280-282
    CrossrefPubMedGoogle Scholar
  • 49 Martinowitz U, Varon D, Yonash P, Bar-Maor A, Brenner B, Leibovitch I, Heim M. Circumcision in hemophilia:the use of fibrin glue for local hemostasis. J Urol 1992; 148: 855-857
    CrossrefPubMedGoogle Scholar
  • 50 Martinowitz U, Schulman S, Gitel S, Horoszowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Brit J Haematol 1992; 82: 729-734
    CrossrefPubMedGoogle Scholar
  • 51 Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemostas 1994; 72: 403-407
    PubMedGoogle Scholar
  • 52 Schulman S, Gitel SN, Zivelin A, Mandalaki T, Katsarou O, Varon D, Martinowitz U. The feasibility of using factor IX concentrates for continuous infusion. Haemophilia. 1995 1. in press
    PubMedGoogle Scholar
  • 53 Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Ped Hematol Oncol. 1994 1. (in press.)
    PubMedGoogle Scholar
  • 54 Wepner F, Fries R, Platz H. The use of the fibrin adhesion system for local hemostasis in oral surgery. J Oral Maxillofac Surg 1982; 40: 555-558
    CrossrefPubMedGoogle Scholar
  • 55 Grimm G, Niekisch R. Complications in hemophilic patients under conditions of fibrin sealing. In: Fibrin sealant in operative medicine. Plastic surgery, maxillofacial and dental surgery. Schlag G, Redl H. eds. Springer Verlag, Berlin Heidelberg; 1986. 4 178-182
    CrossrefGoogle Scholar
  • 56 Baudo F, deCataldo F, Landonio G, Muti G. Management of oral bleeding in haemophilic patients. Lancet 1988; 2: 1082 (letter)
    PubMedGoogle Scholar
  • 57 Carmona FG, Monleon V. Tooth extraction, coagulation disorders and fibrin sealant:results after ten years of experience. Update and Future trends in fibrin sealing in surgical and non-surgical fields, Vienna: 1992: 162 (abstract)
    Google Scholar
  • 58 Neukam FW, Reich R, Bartels M, Steinke M, Adam S. Dentoalvelar surgery and tooth extractions in patients with hemophilia A, hemophilia B and v. Willebrand-Jurgens-syndrome. Update and Future trends in fibrin sealing in surgical and non-surgical fields Vienna: 1992: 163 (abstract)
    Google Scholar
  • 59 Bagenholm T, Stigendal L, Tengbom L. Tissucol/fibrin sealant for oral surgery in patients with coagulation disorders. XXI Int Congr of the WFH Mexico City: 1994: 37 (abstract)
    Google Scholar
  • 60 Ginelli G, Bucciarelli P, Misani M, Carpenedo M, Pignanelli M, Moia M. Fibrin glue plus tranexamic acid mouthwashing in patients on oral anticoagulants undergoing dental extractions:a randomized study. XV Congr of the ISTH Jerusalem: 1995. submitted (abstract)
    Google Scholar
  • 61 Femandez-Palazzi F, Rivas S. The use of “fibrin seal” in surgery of coagulation diseases with special reference to cysts and pseudotumors. In: Dohring S, Schulitz KP. eds. Orthopedic problems in hemophilia.. W. Zuckschwerdt Verlag Miinchen-Bem-Wien; 1985. pp 170-179
    Google Scholar
  • 62 Kluft C, Verheijen JH, Jie AFH J, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shut down.a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
    CrossrefPubMedGoogle Scholar
  • 63 Juhan-Vague I, Aillaud MF, Alessi MC. Biological variations in t-PA activity and antigen. in: Kluft C. Tissue type plasminogen activator (t- PA):physiological and clinical aspects. Boca Raton; CRC Press: 1988. 2 69-87
    Google Scholar
  • 64 Gibble JW, Ness PM. Fibrin glue:the perfect operative sealant. Transfusion 1990; 30: 741-747
    CrossrefPubMedGoogle Scholar
  • 65 Martinowitz U, Schulman S, Solomon AS. Resistance of fibrin sealants to proteolysis in a guinea pig eye model. Submitted for publication
    PubMedGoogle Scholar
  • 66 Pipan CM, Glasheen WP, Matthew TL, Gonias SL, Hwang L-J, Jane JA, Spotnitz WD. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res 1992; 53: 402-407
    CrossrefPubMedGoogle Scholar
  • 67 Shurafa M, Macintosh RB. Management of dental extraction in two hemophilia A patients with F VIII inhibitor. J Oral Maxillofac Surg 1987; 45: 698-701
    CrossrefPubMedGoogle Scholar
  • 68 Rickards KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1 (suppl.) 8-13
    PubMedGoogle Scholar
  • 69 van den Ham AC, Kort WJ, Weijma IM, van den Ingh HF G M, Jeekel H. Effect of antibiotics in fibrin sealant CHI healing colonic anastomoses in the rat. Brit J Surg 1992; 79: 525-528
    CrossrefPubMedGoogle Scholar
  • 70 Hashimoto J, Kurosaka M, Yoshiya S, Hirohata K. Meniscal repair using fibrin sealant and endothelial growth factor. Am J Sports Med 1992; 20: 537-541
    CrossrefPubMedGoogle Scholar
  • 71 Kurianski J, Martinowitz U, Bass A, Gitel SN, Adar E, Mor A, Ayalon A, Keller N. Antibiotic incorporation into fibrin glue:antibacterial properties and dose related inhibitory effect on clot formation. Submitted for publication
    PubMedGoogle Scholar
  • 72 McAlister V, O’Dwyer PS, O’Higgins NJ. Effect of fibrin sealant on the healing colonic anastomosis. Brit J Surg 1991; 78: 889 (letter)
    PubMedGoogle Scholar
  • 73 Byme DJ, Hardy J, Wood RA B, Macintosh R, Hopwood D, Cuschieri A. Adverse influence of fibrin sealant on the healing of high risk sutured colonic anastomoses. J R Coll Surg Edinb 1992; 37: 394-398
    PubMedGoogle Scholar
  • 74 de Virgilio C, Dubrow T, Sheppard BB, MacDonald WD, Nelson RJ, Lesavoy MA, Robertson JM. Fibrin glue inhibits intra-abdominal adhesion formation. Arch Surg 1990; 125: 1378-1381
    CrossrefPubMedGoogle Scholar
  • 75 Sheppard BB, de Virgilio C, Bleiweis M, Milliken JC, Robertson JM. Inhibition of intra-abdominal adhesion formation. Am Surg 1993; 59: 786-790
    PubMedGoogle Scholar
  • 76 van den Ham AC, Kort WJ, Weijmo IM, van den Ingh HF G M, Jeekel H. Effect of fibrin sealant on the integrity of colonic anastomoses in rats with faecal peritonitis. Eur J Surg 1993; 159: 425-432
    PubMedGoogle Scholar
  • 77 Chang H, Wu GJ, Pemg WL, Hwang FY, Hung CR. Effects of fibrin glue on hemostasis. J Formosan Med Assoc 1992; 91: 601-607
    PubMedGoogle Scholar
  • 78 Banninger H, Hardegger T, Tolber A, Barth A, Schiipbach P, Reinhart W, Lammle B, Furlan M. Fibrin glue in surgery:frequent development of inhibitors of bovine thrombin and human factor. Brit J Haematol 1993; 85: 525-532
    PubMedGoogle Scholar
  • 79 Maier WA. Fibrin sealant in circumcision. Presentation at:Update and Future Trends in fibrin Sealing in Surgical and Non-Surgical Fields. Vienna, Austria: 1992
    Google Scholar
  • 80 Sindet-Pedersen S, Ramsrom G, Bemvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant treated patients undergoing oral surgery. N Engl J Med 1989; 320: 840-843
    CrossrefPubMedGoogle Scholar
  • 81 Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe F XI deficiency without plasma replacement. Blood Coag Fibrinol 1992; 91: 601-607
    PubMedGoogle Scholar